Standout Papers

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized... 2022 2026 2023 2024143
  1. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial (2022)
    Thomas Powles, Kobe Yuen et al. Nature Medicine

Immediate Impact

5 by Nobel laureates 25 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Principles and therapeutic applications of adaptive immunity
2024 Standout
3 intermediate papers

Works of Patrick Williams being referenced

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
2022 Standout
Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)
2020

Author Peers

Author Last Decade Papers Cites
Patrick Williams 235 344 287 262 29 1.1k
Seiji Kojima 219 304 213 175 40 1.1k
Yayoi Sato 211 427 200 266 44 1.4k
Joseph E. Gootenberg 247 225 396 208 25 1.4k
John Chapin 144 251 109 149 26 1.1k
Karen M. Helm 234 393 252 230 35 1.3k
Aline B. Scandurro 342 463 238 398 20 1.2k
Annarita Farina 102 505 253 110 38 1.1k
Johan Rebetz 391 275 121 168 34 1.2k
Cinzia Manuelli 478 242 127 339 30 1.1k
Peipei Guo 187 583 190 87 29 1.3k

All Works

Loading papers...

Rankless by CCL
2026